Last updated on August 2018

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)


Brief description of study

This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE).

-The drug involved in this study is Eribulin

Detailed Study Description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.

The FDA (the U.S. Food and Drug Administration) has not approved Eribulin for your specific disease but it has been approved for other uses.

In this research study, the investigators are studying how safe and effective eribulin is in participants with Angiosarcoma or EHE.

Eribulin was created to mimic the structure of a chemical that is released from a sea sponge. The investigators believe that this drug has anti-cancer effects on tumors by blocking proteins called microtubules, among other functions. It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die similar to other drugs that target microtubules

Clinical Study Identifier: NCT03331250

Contact Investigators or Research Sites near you

Start Over

Gregory M Cote, MD, PhD

Massachusetts General Hospital
Boston, MA United States
  Connect »

Katherine Thornton, MD

Dana Farber Cancer Institute
Boston, MA United States
  Connect »